Viser 320 bedrifter for "Pharmaceuticals"
Bedrifter
Theravance Biopharma focuses on delivering medicines that make a difference in people's lives, leveraging decades of expertise to develop treatments for specialty respiratory and neurologic diseases. Key products include YUPELRI® (revefenacin) for COPD and ampreloxetine for symptomatic neurogenic orthostatic hypotension. The company aims to transform treatment through discovery, development, and commercialization, with a commitment to creating shareholder value. They strategically focus on innovation, outsourcing non-core processes, and integrated environment.
Bausch Health is a global, diversified pharmaceutical company with a mission to improve people’s lives through pharmaceutical products. They develop, manufacture, and market products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and international pharmaceuticals. With their leading brands, they are dedicated to advancing global health and fulfilling commitments to patients and healthcare providers.
Tarsus is a biopharmaceutical company dedicated to creating new categories in eye care and beyond. They are driven by a commitment to serving patient needs and changing lives by treating the root cause of disease. Their key product is XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first FDA-approved treatment for Demodex blepharitis. They also have a robust pipeline to address significant unmet patient needs.
Astria Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for rare and niche diseases. They are committed to addressing unmet needs and improving the quality of life for patients, with a focus on scientific innovation and compassion. Their pipeline includes Navenibart (STAR-0215) and STAR-0310, targeting specific therapeutic areas. They are guided by a patient-centric approach emphasizing urgency and operational efficiency.
Winpak is a global packaging group with manufacturing facilities in North America. They manufacture and distribute packaging materials and machines primarily for perishable foods, beverages, pharmaceuticals, medical, and personal care. Winpak specializes in flexible packaging, rigid packaging & lidding, and packaging machinery. They partner with Wipak to offer a broad range of packaging solutions globally.
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for cancer patients in need of new treatment options. They focus on correcting dysregulated gene expression in cancer cells through targeted protein inhibition and targeted protein degradation. Their lead protein inhibitor, seclidemstat (SP-2577), is in phase 1/2 trials, and their TPD drug SP-3164 is in IND-enabling studies. Salarius is the recipient of a CPRIT award and is located in the Texas Medical Center Innovation facility.
X4 is developing and commercializing innovative therapies for rare diseases of the immune system with significant unmet needs. They have successfully developed mavorixafor, approved as XOLREMDI®, and are advancing it for additional patient populations. The company is conducting a global Phase 3 trial (4WARD) for certain chronic neutropenic disorders. X4 is headquartered in Boston and publicly traded on Nasdaq.
Spyre Therapeutics is developing next-generation antibodies engineered for prolonged activity and formulated for delivery as monotherapies or combination therapies. Their innovative approach enables the exploration of treatment options with the potential to deliver uncompromising efficacy and convenience. They target IBD and other immune-mediated diseases. Their pipeline includes novel antibodies targeting validated mechanisms with potential to treat gastrointestinal and rheumatic conditions.
Kezar Life Sciences develops innovative small molecule therapies targeting intracellular proteins to inhibit disease-driving cellular pathways. They focus on Selective Immunoproteasome Inhibition for autoimmune diseases and Protein Secretion Inhibition for cancer and autoimmune diseases. Their mission is to deliver unique treatments for difficult-to-treat chronic diseases.
Zentalis is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. Utilizing its Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors. They also advance research on protein degraders.
CampusPharma registrerer og markedsfører legemidler og egenomsorgsprodukter i Norden, med fokus på kvinnehelse. De tilbyr produkter innen områder som bakteriell vaginose, svangerskapskvalme, menopause og nevrologi. Natalben er et kosttilskudd for gravide og ammende mødre, og Postafen er et reseptfritt legemiddel mot reisesyke.
Q32 Bio is developing innovative therapies to rebalance the immune system, focusing on autoimmune and inflammatory diseases like alopecia areata. Their lead product candidate, Bempikibart (ADX-914), is an anti-IL-7Rα antibody blocking IL-7 and TSLP signaling. The company is in Phase 2 clinical development.
Amphastar Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products. They offer complex medications including biologics and biosimilars, along with innovative drug delivery systems. With multiple manufacturing facilities and a research center, the company is committed to high quality. Amphastar's BAQSIMI® is the #1 prescribed glucagon in the US.
Day One Biopharmaceuticals is focused on developing first- or best-in-class medicines for childhood and adult cancers. They aim to accelerate targeted treatments for patients of all ages. Their approach seeks to disrupt traditional drug development, ensuring faster access to life-changing therapies.
This company is developing a new class of targeted radiotherapeutics designed to deliver radiation directly to tumors in adults and children battling rare and difficult-to-treat cancers. They leverage novel drug formulations and technologies to deliver a single, safe, and effective dose of radiation with minimum toxicity to healthy cells. Their approach aims to preserve normal cell and tissue functioning.
Senti Bio is a clinical-stage biotechnology company developing next-generation cell and gene therapies using synthetic biology. They utilize Gene Circuits to precisely kill cancer cells and spare healthy ones. Their lead product candidate, SENTI-202, is in clinical trials for the treatment of acute myeloid leukemia (AML). The company positions itself as a leader in the cell and gene therapy landscape.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages ~200 billion oncology-focused data points to help solve real-world problems in cancer drug development. By harnessing the power of AI and with input from scientific advisors, we have accelerated the development of our growing pipeline of precision therapies.
Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Their goal is to create a new paradigm in CVD management and to make a life-changing impact on patients’ lives globally. They focus on discovering, developing and delivering innovative treatments and new therapeutic approaches in CVD.
Accon Group is a leading supplier of bulk packaging in the Nordic region, with over 30 years of experience. They offer intelligent packaging and material handling solutions for industries such as food, agriculture, pharmaceuticals, and environment. Accon focuses on quality-assured, sustainable solutions and long-term customer relationships. Their core business includes consulting throughout the entire project process.
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic drugs for rare and orphan diseases. They have a pipeline targeting various rare indications, including Netherton Syndrome. They plan to establish sales infrastructure in the US, Europe, and Japan and have marketing partnerships in 60 countries. They aim to bring hope to patients with unmet medical needs.